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To the Editor:
Latvia is a high-priority country in the fight against tuberculosis (TB) in Europe, with an estimated TB
incidence of 41 per 100000 in 2015 [1]. In spite of an improving TB control programme [2] and cure
rates reaching 80% for new and retreatment TB cases notified in 2014, multidrug-resistant (MDR-) TB
(defined as TB resistant to rifampicin and isoniazid) rates in Latvia remain high [1]. An estimated 8% of
new cases and 30% of retreatment TB cases were at least rifampicin-resistant (RR) in 2015 [1]. Cure rates
in Latvia were 68% for the 2013 RR/MDR-TB cohort [1]. Of all the MDR-TB patients registered in 2015,
25% had extensively drug-resistant (XDR-) TB (defined as MDR-TB with additional resistance to a
fluoroquinolone and a second-line injectable drug) [1].
Delamanid (Deltyba), a nitroimidazooxazole derivative, is an anti-TB drug exhibiting potent in vitro and
in vivoantitubercular activity against drug-susceptible and -resistant strains of Mycobacterium tuberculosis
[3, 4]. It was approved in the European Union in 2014 and included in the World Health Organization
(WHO)’s MDR-TB treatment guidance [5]. Latvia was among the first countries to initiate treatment with
delamanid following its approval in the EU. We present here a retrospective, post-marketing national
cohort study describing the final treatment outcomes of MDR- and XDR-TB patients receiving delamanid
in Latvia between July 2014 and August 2016.
All diagnosed TB patients and their final treatment outcomes in Latvia are recorded in the National
TB Register, which was used as the data source for this study. All cultures positive for Mycobacterium
tuberculosis undergo drug susceptibility testing against first-line and second-line drugs. Specimens from
suspected MDR-TB cases are tested with the Xpert MTB/RIF assay (Cepheid, Sunnyvale, CA, USA);
empirical second-line treatment is started immediately upon receipt of an RR result. Patients are managed
in accordance with WHO recommendations and under an expert consilium [6–8].
Patients with laboratory-confirmed MDR-, pre-XDR (defined as MDR-TB with resistance to either a
fluoroquinolone or second-line injectable agent, but not both [9]) and XDR-TB were selected for
treatment with delamanid when no other treatment options were available, i.e. for reasons of resistance or
tolerability.
The following information was recorded from the national TB register for all patients: age, sex, type and
category of TB, presence of cavities at the start of treatment, HIV status, body mass index, presence/
absence of diabetes mellitus, TB treatment history, optimised background regimen (OBR) in addition to
delamanid, sputum culture status, and final treatment outcome. Data were collected in an MS Excel file
(Microsoft version 2010, Redmond, WA, USA) and analysed with descriptive statistics and frequency
counts. Approval for the study was received in November 2015 from the University of Latvia ethics
committee.
19 patients who received delamanid had final treatment outcomes as of August 2016. Of the 19 patients,
15 (78.9%) were male. The mean age was 41.5 years (range: 11–66), and 17 (89.5%) patients were
⩾18 years of age. All 19 (100%) patients had pulmonary disease, and two (10.5%) patients had pulmonary
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Companion drugs Final treatment outcome
at the end of MDR-TB
treatment
1 30 M Pre-XDR H, R, E, Z, Am, Km, Cm,
PAS
Z, Cm, Mfx, Pto,
Trd, PAS
9 (36) 14 Z, Cm, Mfx, Pto,
Trd
Cured
2 63 M MDR H, R, E Z, Cm, Lfx, Pto,
Trd, PAS
6 (24) 16 Z, Lfx, Pto, Trd Cured
3 56 M XDR H, R, E, Am, Km, Cm, Ofx,
Lfx, Trd, low-dose Mfx
H, R, E, Z 11 (44) 0 Mfx, Lzd, Pto,
Amx/Clv
Cured




10 (40) 13 Z, Mfx, Lzd, PAS Cured
5 66 M Pre-XDR H, R, E, Z, Cm, Pto, PAS No prior
treatment
9 (36) 12 Z, Am, Lfx, Lzd,
Trd
Cured
6 44 M Pre-XDR H, R, E, Z, Am, Km, Cm,
Pto
Z, Mfx, Pto, Trd,
PAS
10 (40) 16 Lfx, Lzd, Trd,
Amx/Clv
Lost to follow-up




3 (12) 18 Trd, PAS, Amx/Clv Cured
8 56 M XDR H, R, E, Z, Km, Ofx, Lfx,
PAS, low-dose Mfx
H, R, E, Z 9 (36) 0 Z, Cm, Mfx, Pto,
Trd
Cured
9 22 M XDR H, R, E, Z, Cm, Ofx, Lfx,
Mfx, PAS
E, Z, Cm, Lfx,
Pto, Trd
6 (24) 7 Z, Am, Mfx, Lzd,
Pto, Trd
Lost to follow-up
10 25 M XDR H, R, Z, Km#, Cm#, Ofx,
Lfx, Mfx, PAS
H, R, E, Z 9 (36) 14 Z, Am, Lzd, Pto,
Trd
Cured
11 48 M XDR H, R, E, Z, Am, Km, Cm,




13 (52) 13 Mfx, Lzd, PAS,
Imp/Cls, Amx/Clv
Cured
12 13 F Pre-XDR H, R, E, Am, Km, Cm, Pto No prior
treatment
6 (24) 11 Z, Cm, Mfx, Trd,
Amx/Clv
Cured
13 56 M Pre-XDR H, R, E, Z, Ofx, Lfx,
low-dose Mfx, Pto, PAS
No prior
treatment
14 (58) 0 Mfx, Lzd, Trd,
Amx/Clv
Cured
14 11 F XDR H, R, E, Z, Am, Km, Ofx,
Lfx, low-dose Mfx, Pto
No prior
treatment
6 (24) 0 Z, Cm, Mfx, Lzd,
Trd
Cured
15 35 M XDR H, R, E, Z, Cm, Ofx, Lfx,
Mfx, Pto, PAS
Z, Am, Pto, Trd,
Lzd, Amx/Clv
11 (44) 19 Z, Am, Lzd, Trd,
Amx/Clv
Cured
16 53 M MDR H, R, E, Z, E, Z, Lfx, Pto,
Trd, PAS
2 (7) 12 Z, Lfx, Lzd, Pto,
Trd
Lost to follow-up




6 (24) 18 Am, Lzd, Trd,
Amx/Clv
Cured




6 (24) 19 Lfx, Lzd, Pto, Trd Cured
19 36 F XDR H, R, E, Z, Am, Km, Cm,




3 (12) 16 Lzd, Imp/Cls,
Amx/Clv
Cured
Cured: treatment completed as recommended by the national policy without evidence of failure, and three or more consecutive cultures taken at least 30 days apart are negative after the
intensive phase. TB: tuberculosis; MDR: multidrug-resistant; XDR: extensively drug-resistant; H: isoniazid; R: rifampicin; E: ethambutol; Z: pyrazinamide; Am: amikacin; Km: kanamycin;
Cm: capreomycin; PAS: para-aminosalicylic acid; Mfx: moxifloxacin; Pto: protionamide; Trd: terizidone; Lfx: levofloxacin; Ofx: ofloxacin; Lzd: linezolid; Amx: amoxicillin; Clv: clavulanate;

















with additional extrapulmonary disease (the first with intestinal TB, and the second with urogenital TB
and a submandibular TB positive abscess). 13 patients (68.4%) had received previous treatment for TB
including one or more second-line TB drugs. Of the 19 patients, two (10.5%) had MDR-TB, eight (42.1%)
had pre-XDR-TB, and nine (47.4%) had XDR-TB. Only one patient (5.3%) was HIV-positive, and no
patient (0.0%) had diabetes. 11 (57.9%) patients had no cavities present, five (26.3%) had unilateral
cavities, and three (15.8%) had bilateral cavities (table 1).
The OBR included terizidone (n=15, 78.9%), linezolid (n=14, 73.7%), pyrazinamide (n=11, 57.9%),
moxifloxacin (n=9, 47.4%), amoxicillin/clavulanate (n=9, 47.4%), protionamide (n=8, 42.1%), amikacin
(n=5, 26.3%), levofloxacin (n=5, 26.3%), capreomycin (n=4, 21.1%), para-aminosalicylic acid (n=3, 15.8%),
and imipenem/cilastatin (n=2, 10.5%).
The mean treatment duration with delamanid was 31.2 weeks (range 7–58), and 16 (84.2%) patients
received delamanid for at least 24 weeks. Three patients (15.8%) received delamanid for <24 weeks. In two
patients, delamanid replaced bedaquiline treatment after the completion of a full course of bedaquiline. In
the third case, the patient’s delamanid treatment was stopped after 2 months when drug susceptibility
testing results became available and an effective MDR-TB regimen could be composed without delamanid.
10 patients (52.6%) received delamanid for longer (36–58 weeks) than the label-approved 24-week
treatment duration; all 10 had either pre-XDR-TB (n=5) or XDR-TB (n=5).
Final treatment outcomes were as follows: 16 patients (84.2%) were classified as cured (treatment
completed as recommended by the national policy without evidence of failure, and three or more
consecutive cultures taken at least 30 days apart are negative after the intensive phase), three patients
(15.8%) were lost to follow-up, and there were no deaths or treatment failures. Amongst the patients lost
to follow-up, all three were culture negative for M. tuberculosis prior to default, and their total MDR-TB
treatment duration ranged from 7 to 16 months. The overall MDR-TB treatment duration for the 16 cured
patients ranged from 11 to 19 months (mean 15 months). Following the Latvian national programme
recommendations following cure, patients are followed up every 6 months, including sputum evaluation.
To date, no relapse has been registered among the 19 patients.
ECG was performed typically once a month, or more often if deemed necessary, during patients’ MDR-TB
therapy. The QTcF (QT interval corrected by Fridericia’s method) value did not exceed 500 ms for any
patient (0.0%) and hepatotoxicity was not reported for any patient. No other clinically relevant adverse
events were attributed to delamanid treatment.
This report represents the first cohort of final treatment outcomes for delamanid patients in the Latvian
programmatic setting. The 19 patients in this cohort study represent severe MDR-TB cases, with 17
patients (89.5%) having pre-XDR or XDR-TB (eight (42.1%) with unilateral or bilateral cavitary disease)
and two (10.5%) with additional extrapulmonary disease. Thus, the prognosis for these patients was
expected to be poor. However, 84.2% (16 out of 19) of patients were cured and, based on the last culture
result available, patients lost to follow-up were all sputum negative. In contrast, a study of 1779 registered
MDR-TB patients in Latvia from 2000 to 2010 showed cure rates of 67% and 50% for MDR-TB and
XDR-TB, respectively [10].
Many of the patients included in the present cohort required delamanid treatment beyond 24 weeks, but the
overall MDR-TB treatment duration in patients that completed MDR-TB therapy was shorter (mean
15 months, range 11–19 months) than the standard 18–24 months. Reasons for the shorter overall MDR-TB
treatment durations were quick conversion, effective medications at treatment start, good tolerance to
regimens, and low frequency of bilateral cavitation. Recently, the WHO recommended the use of a shorter
standard MDR-TB regimen under specific conditions [11]. The feasibility of implementing shorter
MDR-TB treatment regimens utilising delamanid is currently being explored in several studies [12].
Adverse events were consistent with symptoms and complications of TB and comorbidities, and do not
appear to add to the frequency or severity of previously reported adverse events for delamanid [13, 14].
Notably, QTc interval prolongation was of lower frequency than reported in clinical trials, reflecting other
reports from the use of delamanid in programmatic settings [12, 13]. Furthermore, consistent with data
throughout its clinical development programme, delamanid did not contribute to hepatotoxicity [12–16].
This study supports the effectiveness and safety of delamanid in the treatment of MDR-TB in a
programmatic setting, and reflects the current favourable outcomes in MDR-TB patients with advanced
disease treated within Latvia’s state programme for treatment of lung disease.
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